Skip to content
Delayed ~15 min

VIR VIR BIOTECHNOLOGY

Permanent stock page ↗

Health Care · Russell 2000

Next earnings: not announced yet

What 11 analyst firms say about VIR BIOTECHNOLOGY: their latest ratings, price targets and how far the stock is from them. How it works

12.21 USD+1.19 (+10.80%) today
Price as of 6 Nov 16:00 ET

Analyst window: Latest analyst report within last 1 year

Analyst view · last 1Y

+78.1%to the avg target 21.75 USD+9.54 USD
Buy 8 · Hold 0 · Sell 1

9 rated views · 11 analyst/firm records · 11 firms

Latest report8 Oct 2026avg report date 24 Aug
Target rangePrice is below every target

Radar score

  • Russell 2000 · Top Picks · 6MBelow the Radar threshold of 8064
  • Russell 2000 · Safest consensus · 6MBelow the Radar threshold of 8048

Recent analyst activity · last 90 days

Our tracked history has 9 reports on VIR from 7 analyst firms in the last 90 days (11 firms in the past year).

Comparing each firm's latest target with its previous one: 1 raised its price target, 1 lowered it and 3 left it unchanged.

No firm's latest available rating differs from its previous one.

Latest observed target change: Needham raised its target from $18.00 (set 15 Sep 2026) to $20.00 on 5 Nov 2026.

Last 1 year. Latest opinion per identifiable analyst within the last 1 year. BUY / HOLD / SELL each count one current analyst vote; unnamed firm records are a fallback.

FirmAnalystLatest ratingReport dateLatest target (USD)
BarclaysEtzer DaroutBuy8 Oct 202630.00 USD
Evercore ISICory KasimovBuy8 Jun 202622.00 USD
Goldman SachsPaul K ChoiBuy25 Jun 202621.00 USD
H.C. WainwrightPatrick R. TrucchioBuy7 Oct 202622.00 USD
Leerink PartnersRoanna RuizBuy1 Sep 202617.00 USD
Morgan StanleyMichelle Gilson—6 Aug 202625.00 USD
NeedhamJoseph R StringerBuy15 Sep 202618.00 USD
Raymond JamesSean MccutcheonBuy28 Sep 202619.00 USD
TD CowenPhilip M NadeauBuy15 Jun 2026—
Weiss RatingsUnnamed analyst—2 Oct 2026—
Data feed RESEARCHResearch TeamSell6 Oct 2026—

Partial coverage · checked 6 Nov (6 Nov 2026, 03:01 ET). Some research records could not be refreshed. Cached records retained. Prices stream live during the US session; otherwise stored prices delayed about 15 minutes. A summary of analyst opinion, not investment advice.